Abstract
Background The influence of coronavirus disease-2019 (COVID-19) containment measures on variants of concern (VOC) has been understudied in Canada. Our objective was to identify provinces with disproportionate prevalence of VOC relative to COVID-19 mitigation efforts in provinces and territories in Canada.
Methods We analyzed publicly available provincial- and territorial-level data on the prevalence of VOCs in relation to mitigating factors (summarized in three measures: 1. strength of public health countermeasures: stringency index, 2. how much people moved about outside their homes: mobility index, and 3. vaccine intervention: proportion of Canadian population fully vaccinated). Using spatial agglomerative hierarchical cluster analysis (unsupervised machine learning), the provinces and territories were grouped into clusters by stringency index, mobility index and full vaccine coverage. Kruskal-Wallis test was used to determine the differences in the prevalence of VOC (Alpha, or B.1.1.7, Beta, or B.1.351, Gamma, or P.1, and Delta, or B.1.617.2 variants) between the clusters.
Results Three clusters of vaccine uptake and countermeasures were identified. Cluster 1 consisted of the three Canadian territories, and characterized by higher degree of vaccine deployment and lesser degree of countermeasures. Cluster 2 (located in Central Canada and Atlantic region) was typified by lesser implementation of vaccine deployment and moderate countermeasures. The third cluster was formed by provinces in the Pacific region, Central Canada, and Prairie region, with moderate vaccine deployment but stronger countermeasures. The overall and variant-specific prevalence were significantly different across the clusters.
Interpretation This study found that implementation of COVID-19 public health measures varied across the provinces and territories. Considering the high prevalence of VOCs in Canada, completing the second dose of COVID-19 vaccine in a timely manner is crucial.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by CIHR Coronavirus Variants Rapid Response Network grant (Nominated Principal Applicant: Marc-Andre Langlois; a co-applicant: Nazeem Muhajarine)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical consideration This analysis centred on publicly available data with no identifiable information about the people studied. Therefore, research ethics board approval was not required for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contributions The corresponding author and supervisor for this study is Nazeem Muhajarine. Nazeem Muhajarine and Daniel Adeyinka were responsible for the conception and development of the study. Daniel Adeyinka acquired the data and completed statistical analysis of the data. Daniel Adeyinka drafted the manuscript, and Nazeem Muhajarine, Cheryl Camillo and Wendie Marks revised the manuscript for important intellectual content. All the authors approved the final version for publication and agreed to be accountable for the work.
Competing interests No competing interest declared, financial or otherwise.
Funding This work is supported by CIHR Coronavirus Variants Rapid Response Network grant (Nominated Principal Applicant: Marc-Andre Langlois; a co-applicant: Nazeem Muhajarine).
Data Availability
Data sharing: Data on cumulative number of VOC cases can be downloaded from CTV News COVID-19 variants of concern tracker,4 and vaccine coverage rates are available at the COVID-19 Vaccination Tracker. Provincial- and territorial-level population estimates are available from Statistics Canada. Stringency index can be obtained at Oxford COVID-19 Government Response Tracker (OxCGRT) website. The mobility reports can be downloaded from Google LLC. Researchers who require access to the study data can contact the corresponding author for further information (nazeem.muhajarine@usask.ca).
